NCT05782777Recruiting
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary revascularization with newer generation drug-eluting stent (DES) implantation. Furthermore, the optimal OCT-based optimal expansion criteria as well as the efficacy and safety of newer generation will be investigated.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 4310 (estimated)
- First submitted
- 29 Jan 2023
- Start date
- 7 Apr 2023
- Primary completion date
- Dec 2027
- Lead sponsor
- Yonsei University
- Diseases
- Coronary artery disease
- NCT number
- NCT05782777
What you commit to
- Study type: Interventional
- Planned participants: 4310
- From 7 Apr 2023 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy or hypersensitive to ezetimibe or statin
- History of any adverse drug reaction requiring discontinuation of statin
Lab values
- Active liver disease or persistent unexplained serum AST/ALT elevation more than 2 times the upper limit of normal range
Other
- Pregnant women, women with potential childbearing, or lactating women
- Life expectancy less than 3 years
- Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
- Inability to understand or read the informed consent
Who the study is looking for
- Age 19-85 years
- Patients who underwent coronary revascularization with newer generation DES implantation
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yonsei University Health System, Severance Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.